OMER
- Omeros Corporation
()
Overview
Company Summary
Omeros Corporation is a biopharmaceutical company that specializes in developing and commercializing innovative therapeutics for various medical conditions. The company primarily focuses on discovering and developing small-molecule and protein therapeutics to target inflammation, disorders of the central nervous system (CNS), and immune-related diseases.
One of Omeros Corporation's key products is OMS721, a monoclonal antibody that targets a protein called mannan-binding lectin-associated serine protease-2 (MASP-2). This product has shown promising results in the treatment of several disorders, including hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and immunoglobulin A (IgA) nephropathy.
Omeros also has a product called OMS527 in its pipeline, which is a phosphodiesterase 10 (PDE10) inhibitor. PDE10 is an enzyme found in the CNS and plays a role in regulating brain function. OMS527 is being developed for the treatment of movement disorders, such as Huntington's disease and schizophrenia.
Furthermore, Omeros utilizes its proprietary PharmacoSurgery platform to discover drugs that selectively inhibit inflammation. Their approach aims to reduce inflammation during surgical and traumatic conditions, thereby improving patient outcomes.
In addition to these advancements, Omeros has ongoing research and development programs targeting other diseases, including addiction, cancer, and immune-related conditions. The company also actively engages in partnerships and collaborations with academic institutions and pharmaceutical companies to leverage their expertise and expand its therapeutic offerings.
Overall, Omeros Corporation is dedicated to developing innovative therapies that address unmet medical needs in various therapeutic areas, with a particular focus on inflammatory and CNS disorders.